MAP2K7 and cancer: Similarly, xenograft models have demonstrated synergistic actions when ganetespib and vemurafenib, or specific MEK inhibitors, are combined; ganetespib and the MEK inhibitor TAK-733 together also significantly reduced the tumor size in vemurafenib-resistant xenograft tumors in a preclinical investigation, supporting the utility of this combination to treat cancers that have acquired a resistance to vemurafenib [109].